ArticleJournal of ophthalmology2026
Changing Epidemiology of Refractive Disorders in the Western Pacific Region, 1990-2023: Evidence From the Global Burden of Disease Study 2023.
Article in Journal of ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Refractive disorders (RDs) are a major cause of vision impairment worldwide. Although age-standardised rates have generally declined, the absolute burden, demographic drivers and future trends of RDs in the Western Pacific Region (WPR) remain incompletely characterised. This study assessed the long-term epidemiological patterns and projected burden of RDs in the WPR using data from the Global Burden of Disease Study 2023 (GBD 2023). Materials and Methods: Data on prevalent cases, prevalence and disability-adjusted life years (DALYs) due to RDs from 1990 to 2023 were obtained from GBD 2023. Age-standardised prevalence rates (ASPRs) and age-standardised DALY rates (ASDRs) were evaluated globally and across 31 countries and territories in the WPR. Temporal trends were assessed using estimated annual percentage change and joinpoint regression. Age- and sex-specific patterns were examined, and Shapley decomposition was used to quantify the contributions of population growth, population ageing and epidemiological change. ARIMA models were used to project ASPR and ASDR to 2030. Results: In the WPR, prevalent cases increased from 23.45 million in 1990 to 39.75 million in 2023, while ASPR declined from 1606.27 to 1382.90 per 100,000 population. DALYs increased from 1.09 million to 1.75 million, whereas ASDR declined from 76.00 to 59.85 per 100,000. Age-specific burden increased markedly with age, and females generally experienced a higher burden than males, particularly in middle and older age groups. Joinpoint analyses identified long-term declines in ASPR and ASDR but modest rebounds after 2019. Population growth was the dominant positive contributor to increasing absolute burden in most WPR countries, while population ageing contributed substantially, particularly in East Asia and among females; epidemiological change generally offset part of these demographic increases. By 2030, ASPR and ASDR in the WPR were projected to decline further to 1317.70 (95% PI 1282.64-1352.76) and 55.00 (95% PI 52.66-57.34) per 100,000, respectively. Conclusion: Despite declining age-standardised rates, the absolute burden of RDs in the WPR continues to increase under demographic pressure. Continued population growth and ageing, together with persistent age and sex disparities, indicate that declining rates alone may underestimate future eye-care needs. Monitoring both age-standardised and absolute burden, alongside effective refractive error coverage, will be important for regional planning and progress towards the WHO 2030 targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.